Tradename | Company | Number | Date | Products |
---|---|---|---|---|
ZORYVE | Arcutis Biotherapeutics | N-215985 RX | 2022-07-29 | 2 products, RLD, RS |
ZORYVE | Arcutis Biotherapeutics | N-217242 RX | 2023-12-15 | 1 products, RLD, RS |
DALIRESP | AstraZeneca | N-022522 RX | 2011-02-28 | 2 products, RLD, RS |
Brand Name | Status | Last Update |
---|---|---|
daliresp | New Drug Application | 2020-03-12 |
roflumilast | ANDA | 2025-03-21 |
zoryve | New Drug Application | 2025-02-21 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
chronic obstructive pulmonary disease | EFO_0000341 | D029424 | J44.9 |
Expiration | Code | ||
---|---|---|---|
ROFLUMILAST, ZORYVE, ARCUTIS | |||
2025-07-29 | NP | ||
ROFLUMILAST, ROFLUMILAST, MSN | |||
2023-04-18 | PC | ||
ROFLUMILAST, ROFLUMILAST, HETERO LABS LTD III | |||
2023-04-17 | PC | ||
ROFLUMILAST, ROFLUMILAST, MYLAN | |||
2023-04-17 | PC | ||
ROFLUMILAST, ROFLUMILAST, STRIDES PHARMA | |||
2023-04-17 | PC |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Chronic obstructive pulmonary disease | D029424 | EFO_0000341 | J44.9 | 1 | 2 | 14 | 2 | 6 | 24 |
Obstructive lung diseases | D008173 | — | — | 1 | 2 | 13 | 2 | 4 | 21 |
Lung diseases | D008171 | EFO_0003818 | J98.4 | — | 2 | 12 | 2 | 2 | 17 |
Respiratory tract diseases | D012140 | — | — | — | — | — | 1 | — | 1 |
Respiration disorders | D012120 | — | J00-J99 | — | — | — | 1 | — | 1 |
Disease progression | D018450 | — | — | — | — | — | 1 | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Asthma | D001249 | EFO_0000270 | J45 | — | 3 | 6 | — | — | 8 |
Respiratory signs and symptoms | D012818 | — | — | — | — | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 1 | 1 | — | — | — | 2 |
Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | 1 | 1 | — | — | — | 2 |
Atopic dermatitis | D003876 | EFO_0000274 | L20 | — | 2 | — | — | — | 2 |
Eczema | D004485 | — | L30.9 | — | 2 | — | — | — | 2 |
Dermatitis | D003872 | — | L30.9 | — | 2 | — | — | — | 2 |
Non-alcoholic fatty liver disease | D065626 | EFO_0003095 | K75.81 | — | 1 | — | — | — | 1 |
Fatty liver | D005234 | EFO_0003934 | — | — | 1 | — | — | — | 1 |
Inflammation | D007249 | MP_0001845 | — | — | 1 | — | — | — | 1 |
Psoriasis | D011565 | EFO_0000676 | L40 | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Memory disorders | D008569 | — | — | 1 | — | — | — | — | 1 |
Alzheimer disease | D000544 | EFO_0000249 | F03 | 1 | — | — | — | — | 1 |
Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
Drug common name | Roflumilast |
INN | roflumilast |
Description | Roflumilast is a benzamide obtained by formal condensation of the carboxy group of 3-(cyclopropylmethoxy)-4-(difluoromethoxy)benzoic acid with the amino group of 3,5-dichloropyridin-4-amine. Used for treatment of bronchial asthma and chronic obstructive pulmonary disease. It has a role as a phosphodiesterase IV inhibitor and an anti-asthmatic drug. It is a member of benzamides, a chloropyridine, an aromatic ether, an organofluorine compound and a member of cyclopropanes. |
Classification | Small molecule |
Drug class | antiasthmatics/antiallergics (not acting primarily as antihistamines): type IV phosphodiesterase |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | O=C(Nc1c(Cl)cncc1Cl)c1ccc(OC(F)F)c(OCC2CC2)c1 |
PDB | — |
CAS-ID | 162401-32-3 |
RxCUI | — |
ChEMBL ID | CHEMBL193240 |
ChEBI ID | 47657 |
PubChem CID | 449193 |
DrugBank | DB01656 |
UNII ID | 0P6C6ZOP5U (ChemIDplus, GSRS) |